Home > Oncology > SABCS 2019 > HER2-Positive Breast Cancer > Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer

Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer

Conference
SABCS 2019
Trial
APHINITY

Data from a 6-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard of trastuzumab plus chemotherapy after surgery continued to reduce the risk of recurrence and death in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. There were fewer deaths in patients treated with pertuzumab, although the survival benefit was not statistically significant at this time.

In its primary analysis, the APHINITY trial demonstrated that pertuzumab when added to adjuvant trastuzumab and chemotherapy statistically significantly (although modestly) improved invasive disease-free survival (iDFS) among patients with HER2-positive, operable breast cancer [1]. Between November 2011 and August 2013, a total of 2,400 patients were randomly assigned to receive pertuzumab whilst 2,404 patients received placebo [2]. The median follow-up was 45.4 months. In the intention-to-treat (ITT) population, the estimates of the...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on